Abbey Spanier Rodd & Abrams, LLP, Announces Class Action Lawsuit on Behalf of Sequenom, Incorporated Sh...( NEW YORK May 6 /- Notice is hereby gi...),Health

NEW YORK, May 6 /PRNewswire/ -- Notice is hereby given that Abbey Spanier Rodd & Abrams, LLP has filed a class action lawsuit in the United States District Court for the Southern District of California on behalf of a class consisting of all persons or entities who purchased the securities of Sequenom Incorporated ("Sequenom" or the "Company") (Nasdaq: SQNM), between June 4, 2008 and April 29, 2009, inclusive (the "Class Period"). The Complaint charges Sequenom and certain of the Company's executive officers with violations of federal securities laws.

A copy of the Complaint is available from the court or from Abbey Spanier Rodd & Abrams, LLP. Please contact us by phone to discuss this action or to obtain a copy of the Complaint at (212) 889-3700, by email at info@abbeyspanier.com, or visit our website at http://www.abbeyspanier.com.

Sequenom provides products, services, diagnostic testing, applications and generic analysis products that translate genomic science into solutions for biomedical research, translational research, molecular medicine and agricultural and livestock applications. The Complaint alleges that throughout the Class Period defendants knew or recklessly disregarded that their public statements concerning Sequenom's business, operations and prospects were materially false and misleading. Specifically, the Complaint alleges that defendants' public statements were false and misleading or failed to disclose or indicate material adverse developments concerning Sequenom's noninvasive SEQureDx prenatal Down Syndrome test ("SEQureDx"), including that: (i) clinical trial tests and data concerning SEQureDx were not being co
'/>"/>